Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Tumor Boards
Colleague Insights
Living Resources
Conferences
Nursing Perspectives
Video Expert Opinion
Sign in
Join now

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Renal Cell Carcinoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

featured
Published in Renal Cell Carcinoma

Expert Opinion / Cases · April 28, 2015

Evaluation for Third Line Therapy

Heather Greene MSN, FNP, AOCNP

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Heather Greene MSN, FNP, AOCNP

Discuss This item Follow

No comments yet, be the first to start the discussion!

  • Bradley Somer MD

    Bradley G. Somer MD

    Apr 29, 2015

    This is a patient who unfortunately is progressing rapidly on mTOR inhibitors. We now know from the INTORSECT study that despite the hypothesis, Torisel is probably less beneficial in second line then we thought, as sorafenib yielded better survival (http://www.practiceupdate.com/c/5879/48/1). Unless there was a contraindication to giving either everolimus or axitinib, would probably have steered away from that course. Thus, under the current circumstances of coming off of an mTOR inhibitor strategy, the standard practice would be to give axitinib given great prior response to VEGF inhibitors and the AXIS trial (http://www.practiceupdate.com/c/3182/48/1). Another consideration is clinical trial availability, possibly with an immune checkpoint inhibitor. 

  • Nov 16, 2024

    Pending Moderator approval.
    Delete

Further Reading

Recently Updated